Analysis of the evolution in the treatment of pulmonary hypertension;Análisis de la evolución del tratamiento de hipertensión pulmonar

Atencion Farmaceutica

Volumn 7, Issue 1, 2005, Pages 54-62

  Cortijo Cascajares, S ^a   Garcia Rodriguez Ma P ^a   Escobar Rodriguez I ^a   Herreros De Tejada Y Lopez Coterilla A ^a  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

Author keywords

Bosentan; Prostacyclins; Pulmonary hypertension; Sildenafil

Indexed keywords

BOSENTAN; ILOPROST; PROSTACYCLIN; SILDENAFIL; UNIPROST;

ADOLESCENT; ADULT; AGED; ARTICLE; FEMALE; HEALTH CARE COST; HOSPITAL PHARMACY; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MONOTHERAPY; PULMONARY HYPERTENSION; RETROSPECTIVE STUDY; SCHOOL CHILD;

EID: 18744396958     PISSN: 11397357     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (15)

1. Rubin LJ. Current concepts: Primary pulmonary hypertension. N Eng J Med 1997; 336: 111-7.
2. Nauser TD, Stiles SW. Diagnosis and treatment of pulmonary hypertension. Am Fam Physician 2001; 63: 1789-98.
3. Crespo C, Morales V, Alonso H, Alonso B, Molero R. Hipertension pulmonar primaria y su tratamiento. Farm Hosp 2004; 28: 48-55.
4. Sulica R, Poon M. Current medical treatment of pulmonary arterial hypertension. Mt Sinai J Med 2004; 71: 103-14.
5. Hipertension pulmonar primaria. Guía de cardiología en internet. URL disponible en: http://www.coresalud.com /Enfermedad/ htppul.htm.
6. Treprotinil (remodulin) for pulmonary arterial hypertension. Med Lett Drugs Ther 2002; 44 (Issue 1139): 80-1.
7. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, et al. Long term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000; 342: 1866-70.
8. Humbert M, Sitbon O, Simonneau G. Treatment of pulmonary Arterial Hypertension. N Engl J Med 2004; 351: 1425-36.
9. Hoeper MM, Galiè N, Simonneau G, Rubin LJ. New treatments for pulmonary arterial hypertension. Am J Respir Crit Care Med 2002; 165: 1209-16.
10. Channick RN, Rubin LJ. New and experimental therapies for pulmonary hypertension. Clin Chest Med 2001; 22: 539-45.
11. Chaouat A, Weitzenblum E. Therapeutic management of primary pulmonary hypertension. Presse Med 2002; 31: 320-8.
12. Channick RN, Rubin LJ. Combination therapy for pulmonary hypertension: A glimpse into the future?. Crit Care Med 2000; 28: 896-7.
13. Hoeper MM, Taha N, Bekjarova A, Gatzke R, Spiekerkoetter E. Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids. Eur Respir J 2003; 22: 330-4.
14. Channick RN, Kim N, Lombardi S. Addition of bosentan to patients with pulmonary arterial hypertension receiving chronic epoprostenol or treprostinil is well tolerated and allows for weaning or discontinuation of prostacyclin in some patients. Am J Crit Care Med 2003; 167: A 441.
15. Stiebellhner L, Petkov V, Vonbank K, Funk G, Schenk P, Ziesche R et al. Long-term treatment with oral sildenafil in addition to continuous IV epoprostenol in patients with pulmonary arterial hypertension. Chest 2003; 123: 1293-5.